...
机译:复发/难治多骨髓瘤(RRMM)患者治疗满意度的患者报告的因素
Icahn School of Medicine at Mount SinaiNew York New York USA;
Millennium Pharmaceuticals Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company;
SanofiCambridge Massachusetts USA;
PatientsLikeMeCambridge Massachusetts USA;
PatientsLikeMeCambridge Massachusetts USA;
PatientsLikeMeCambridge Massachusetts USA;
Millennium Pharmaceuticals Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company;
Relapsed/refractory multiple myeloma; Treatment satisfaction; Time burden; Indirect treatment costs;
机译:复发/难治多骨髓瘤(RRMM)患者治疗满意度的患者报告的因素
机译:日本人总人口和日本人复诊/耐药多发性骨髓瘤(RRMM)的患者报告结果
机译:治疗满意度和疾病的负担(Boi)与口腔vs患者对复发或难治性疾病的患者的可注射多发性骨髓瘤治疗
机译:病例报告:在73岁的患者中成功治疗反对因子VIII的自发获得的抑制剂
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:复发/难治性多发性骨髓瘤(RRMM)患者治疗满意度的患者报告因素
机译:患者报告的复发/难治多骨髓瘤患者治疗的因素(RRMM)